drugset / Trial / NCT00866970
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
RandomizedSingle-groupQuadruple-blindTreatment
Summary
The purpose of this study is to asses the safety and efficacy of ALD518 in patients with Non-Small Cell Lung Cancer-Related Fatigue and cachexia (weight-loss).
Timeline
- Start
- 2008-09
- Primary completion
- 2009-08
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clazakizumab | Monoclonal antibody | 80 mg | Intravenous |
| Subject | Clazakizumab | Monoclonal antibody | 160 mg | Intravenous |
| Subject | Clazakizumab | Monoclonal antibody | 360 mg | Intravenous |